665 results match your criteria WDHA Syndrome

Vasoactive intestinal peptide secreting tumour: An overview.

Esther Una Cidon

World J Gastrointest Oncol 2022 Apr;14(4):808-819

Department of Medical Oncology, University Hospitals Dorset, Bournemouth BH7 7DW, Dorset, United Kingdom.

Vasoactive intestinal peptide (VIP) secreting tumour (VIPoma) is a rare functional neuroendocrine tumour that typically arises from pancreatic islet cells. These present as sporadic, solitary pancreatic neoplasias with an estimated incidence of one in ten million individuals per year. Only around 5% of VIPomas are associated with multiple endocrine neoplasia type I syndrome. Read More

View Article and Full-Text PDF

Localization of VIPoma with NETSpot.

Am Surg 2022 Apr 17:31348221086797. Epub 2022 Apr 17.

21693University of Mississippi Medical Center Department of Surgery, Jackson, MS, USA.

View Article and Full-Text PDF

The VIPoma.

J Trauma Acute Care Surg 2022 Apr 8. Epub 2022 Apr 8.

View Article and Full-Text PDF

Vasoactive Intestinal Peptide-Secreting Pancreatic Neuroendocrine Tumor: A Case Report.

Cureus 2022 Mar 3;14(3):e22819. Epub 2022 Mar 3.

Surgery, Teaching Hospital Jaffna, Jaffna, LKA.

A 36-year-old female with chronic watery diarrhea and persistent hypokalemia for more than eight months duration eventually being diagnosed as vasoactive intestinal peptide tumor (VIPoma) clinically and histologically is presented here. The patient achieved complete recovery after starting octreotide, a somatostatin analog. She underwent a distal pancreatectomy along with the removal of the tumor at Teaching Hospital Jaffna for the permanent cure. Read More

View Article and Full-Text PDF

VIPoma: an unsuspecting culprit of severe secretory diarrhoea in a human immunodeficiency virus-infected patient.

Intern Med J 2022 Jan;52(1):125-129

Department of Infectious Diseases, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.

A 35-year-old man with known human immunodeficiency virus experienced chronic diarrhoea for 18 months. He presented to multiple hospitals with profuse secretory diarrhoea and life-threatening electrolyte disturbances. Infectious and non-infectious aetiologies were considered, with focussed history and investigations ultimately leading to a diagnosis of VIPoma. Read More

View Article and Full-Text PDF
January 2022

Laparoscopic resection of VIPoma presenting at an unusual location.

J Minim Access Surg 2022 Jan 4. Epub 2022 Jan 4.

Department of Surgical Gastroenterology and Minimally Invasive Surgery, Sahasra Hospitals, Bengaluru, Karnataka, India.

VIPoma is an extremely rare neuroendocrine tumour. Majority of the lesions occur in the pancreas. There is usually a long and recurrent history of secretory diarrhoea. Read More

View Article and Full-Text PDF
January 2022

Surgical treatment of metastatic VIPoma: a case report.

Therap Adv Gastroenterol 2021 6;14:17562848211051132. Epub 2021 Dec 6.

Department of General, Visceral, and Pediatric Surgery, University Medical Center Goettingen, Robert-Koch-Straße 40, 37077 Goettingen, Germany.

VIPoma, a neuroendocrine tumour mostly occurring in the human pancreas and producing high levels of vasoactive intestinal peptide, is a rare disease that presents with a wide spectrum of symptoms, including intense diarrhoea, hypokalaemia, and cardiac complications, with life-threatening consequences. In most cases, metastatic lesions are present at VIPoma diagnosis. Treatment options include symptomatic therapy, chemotherapy, radiation and surgery. Read More

View Article and Full-Text PDF
December 2021

Life-threatening diarrhea in neuroendocrine tumors: two case reports.

J Med Case Rep 2021 Oct 27;15(1):542. Epub 2021 Oct 27.

Department of Medical Oncology, Royal North Shore Hospital, St. Leonards, Sydney, NSW, 2065, Australia.

Background: Neuroendocrine tumors are rare, heterogeneous neoplasms that produce a wide variety of clinical symptoms. Diarrhea in neuroendocrine tumors is incredibly common and is usually benign in nature. We report two extreme cases of diarrhea in metastatic neuroendocrine tumors that threatened fatality and provide evidence for steroids as a novel agent in the management of vasoactive intestinal peptide tumors. Read More

View Article and Full-Text PDF
October 2021

[VIPoma of the Pancreas].

Praxis (Bern 1994) 2021 Sep;110(11):637-642

Abteilung für Allgemeine Innere Medizin, Spital Zofingen, Zofingen.

VIPoma of the Pancreas A 50-year old man was admitted for evaluation of progressive, chronic diarrhea with loss of weight and recurrent hypokalemia. Eventually, a neuroendocrine tumor of the pancreas secreting VIP (VIPoma) could be diagnosed. The patient was cured by a pancreaticoduodenectomy (Whipple procedure). Read More

View Article and Full-Text PDF
September 2021

Pancreatic VIPoma as a Differential Diagnosis in Chronic Pediatric Diarrhea: A Case Report and Review of the Literature.

J Med Cases 2021 May 5;12(5):195-201. Epub 2021 Mar 5.

Pediatric Critical Care, University Hospital Fundacion Santa Fe de Bogota, Bogota, Columbia.

Chronic diarrhea is a common chief complaint in the pediatric population with a wide range of diagnostic differentials; as such, whilst suspecting common causes, less prevalent conditions tend to be overlooked, such as neuroendocrine tumor pathologies. VIPomas are characterized by hypersecretion of the vasoactive intestinal peptide (VIP), causing watery diarrhea, hypokalemia, and achlorhydria. Nonetheless, its low incidence rate in children makes it an easily unnoticed pathology. Read More

View Article and Full-Text PDF

Efficacy of treatments for VIPoma: A GTE multicentric series.

Pancreatology 2021 Dec 5;21(8):1531-1539. Epub 2021 Aug 5.

Department of Gastroenterology-Pancreatology, ENETS Centre of Excellence, Hôpital Beaujon and Université de Paris Nord, Clichy, France.

Background: Vasoactive intestinal peptide-secreting tumor (VIPoma) is a very rare, life-threatening, functioning pancreatic neuroendocrine tumor (pNET). The efficacy of antitumor therapies against functioning symptoms and tumor burden have been poorly described in VIPoma.

Objective: Describe the impact of treatments on the secretory syndrome, tumor burden and survival in patients with VIPoma. Read More

View Article and Full-Text PDF
December 2021

Evaluation of the Octreotide Acetate Pen Injector and its Instructions for Use in a Formative Human Factors Study.

Adv Ther 2021 06 4;38(6):3129-3142. Epub 2021 May 4.

Device Development, Sun Pharmaceutical Industries Ltd, Tandalja, Vadodara, Gujarat, India.

Introduction: Octreotide acetate subcutaneous injection is indicated to treat acromegaly and the symptoms of carcinoid tumors and vasoactive intestinal peptide tumors (VIPomas). This formative human factors study assessed the octreotide acetate pen injector and accompanying instructions for use (IFU) with self-trained participants.

Methods: The study enrolled patients with diagnoses of acromegaly, carcinoid tumors, or VIPomas and healthcare practitioners (HCPs) who treat patients with these diagnoses. Read More

View Article and Full-Text PDF

Case Report: Irreversible Watery Diarrhea, Severe Metabolic Acidosis, Hypokalemia and Achloridria Syndrome Related to Vasoactive Intestinal Peptide Secreting Malignant Pheochromocytoma.

Front Endocrinol (Lausanne) 2021 17;12:652045. Epub 2021 Mar 17.

Centro Ipertensione Arteriosa e Studio Malattie Cardiorenali, S.S. Fisiopatologia Medica, Clinica Medica Generale e Terapia Medica, Parma, Italy.

Background: Pheochromocytoma (PHEO) clinical manifestations generally mirror excessive catecholamines secretion; rarely the clinical picture may reflect secretion of other hormones. Watery diarrhea, hypokalemia and achlorhydria (WDHA) is a rare syndrome related to excessive secretion of vasoactive intestinal peptide (VIP).

Clinical Case: A 73-year-old hypotensive man affected by adrenal PHEO presented with weight loss and watery diarrhea associated with hypokalemia, hyperchloremic metabolic acidosis (anion gap 15 mmol/l) and a negative urinary anion gap. Read More

View Article and Full-Text PDF
January 2022

Pancreatoduodenectomy for Neuroendocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1: An AFCE (Association Francophone de Chirurgie Endocrinienne) and GTE (Groupe d'étude des Tumeurs Endocrines) Study.

World J Surg 2021 06 1;45(6):1794-1802. Epub 2021 Mar 1.

Department of Digestive and Endocrine Surgery, Dijon University Hospital, University of Burgundy, Dijon, France.

Aim: To assess postoperative complications and control of hormone secretions following pancreatoduodenectomy (PD) performed on multiple endocrine neoplasia type 1 (MEN1) patients with duodenopancreatic neuroendocrine tumors (DP-NETs).

Background: The use of PD to treat MEN1 remains controversial, and evaluating the right place of PD in MEN1 disease makes sense.

Methods: Thirty-one MEN1 patients from the Groupe d'étude des Tumeurs Endocrines MEN1 cohort who underwent PD for DP-NETs between 1971 and 2013 were included. Read More

View Article and Full-Text PDF

Repurposing calcium-sensing receptor agonist cinacalcet for treatment of CFTR-mediated secretory diarrheas.

JCI Insight 2021 02 22;6(4). Epub 2021 Feb 22.

Department of Pediatrics and.

Diarrhea is a major cause of global mortality, and outbreaks of secretory diarrhea such as cholera remain an important problem in the developing world. Current treatment of secretory diarrhea primarily involves supportive measures, such as fluid replacement. The calcium-sensing receptor (CaSR) regulates multiple biological activities in response to changes in extracellular Ca2+. Read More

View Article and Full-Text PDF
February 2021


Georgian Med News 2020 Nov(308):101-109

Bogomolets National Medical University, Kyiv, Ukraine TARGET Oncology Clinic, Kyiv, Ukraine.

Pancreatic neuroendocrine tumors (NETs) are an urgent problem. The issues of diagnosis and treatment of neuroendocrine tumors (NETs) are currently one of the most complex and relevant ones in modern oncological endocrinology. The growing interest in NETs is due to the fact that the incidence rate of this pathology has increased significantly in the world over the past 30-35 years. Read More

View Article and Full-Text PDF
November 2020

Pancreatic neuroendocrine tumors: Surgical outcomes and survival analysis.

Am J Surg 2021 03 24;221(3):529-533. Epub 2020 Dec 24.

Loyola University Medical Center, Department of Surgery, Maywood, IL, USA.

Background: Pancreatic neuroendocrine tumors are rare, with rising incidence and limited clinicopathological studies.

Methods: Adult patients with pNET at a single tertiary care center were retrospectively evaluated.

Results: In total, 87 patients with histologically confirmed pNET who underwent resection were evaluated. Read More

View Article and Full-Text PDF

Pancreatic neuroendocrine neoplasms: Clinicopathological features and pathological staging.

Histol Histopathol 2021 Apr 11;36(4):367-382. Epub 2020 Dec 11.

School of Medicine, Griffith University, Gold Coast, QLD, Australia.

The nomenclature and classification of pancreatic neuroendocrine neoplasms has evolved in the last 15 years based on the advances in knowledge of the genomics, clinical behaviour and response to therapies. The current 2019 World Health Organization classification of pancreatic neuroendocrine neoplasms categorises them into three groups; pancreatic neuroendocrine tumours (PanNETs)(grade 1 grade 2, grade 3), pancreatic neuroendocrine carcinomas and mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) based on the mitotic rate, Ki-67 index, morphological differentiation and/or co-existing tissue subtype. PanNETs are also classified into non-functional NET, insulinoma, gastrinoma, VIPoma, glucagonoma, somatostatinoma, ACTH-producing NET and serotonin producing NET based on hormone production and clinical manifestations. Read More

View Article and Full-Text PDF

Clinical Characteristics and Management of Functional Pancreatic Neuroendocrine Neoplasms: A Single Institution 20-Year Experience with 286 Patients.

Int J Endocrinol 2020 6;2020:1030518. Epub 2020 Nov 6.

Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, China.

Background: Functional pancreatic neuroendocrine neoplasms (PanNENs) are very rare disorders but have complex spectrum, including insulinoma, gastrinoma, glucagonoma, somatostatinoma, and VIPoma. Patients with PanNENs usually present with characteristic symptoms caused by corresponding hormone hypersecretion. It has always been challenging in dealing with such rare but complicated disorders. Read More

View Article and Full-Text PDF
November 2020

Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes.

Expert Opin Pharmacother 2021 Apr 11;22(6):685-693. Epub 2020 Nov 11.

Digestive Diseases Branch, NIDDK,NIH, Bethesda, MD, USA.

: In the past, controlling the hormone-excess-state was the main determinant of survival in Functional-Neuroendocrine-Neoplasm-syndromes (F-NENs). This was difficult because the pharmacological-armamentarium available was limited. Recently, new therapeutic strategies have increased but it also generated controversies/uncertainties. Read More

View Article and Full-Text PDF

Vasoactive intestinal peptide-oma causing refractory diarrhea in a young woman.

Proc (Bayl Univ Med Cent) 2020 Jul 7;33(4):641-643. Epub 2020 Jul 7.

Division of Gastroenterology, Baylor University Medical Center, Dallas, Texas.

Vasoactive intestinal peptide (VIP)-secreting neuroendocrine tumors are an exceptionally rare cause of chronic diarrhea. We describe a 36-year-old woman presenting with a 2-year history of severe diarrhea and electrolyte derangements ultimately diagnosed with VIPoma. Read More

View Article and Full-Text PDF

An Unusual Cause of Watery Diarrhea.

Gastroenterology 2021 02 8;160(3):671-674. Epub 2020 Oct 8.

Department of Medicine, Division of Gastroenterology and Hepatology, University of Illinois at Chicago, Chicago, Illinois.

View Article and Full-Text PDF
February 2021

Percutaneous Cryoablation of Recurrent Pancreatic Mass for Life-Threatening Pancreatic VIPoma Syndrome: A Case Report.

Cardiovasc Intervent Radiol 2021 Jan 10;44(1):163-166. Epub 2020 Sep 10.

Division of Interventional Radiology, Department of Medical Imaging, London Health Sciences Centre, Western University, London, ON, Canada.

We present the case of a 73-year-old female who underwent percutaneous cryoablation for recurrent life-threatening pancreatic vasoactive intestinal polypeptide-producing tumor (VIPoma) following a pancreaticoduodenectomy and chemotherapy 5 years earlier. She presented with profuse watery diarrhea causing severe electrolyte and acid-base abnormalities, along with acute kidney injury. Cryoablation was successful in treating her profound symptoms, completely reversing her clinical course. Read More

View Article and Full-Text PDF
January 2021

Rare Cases of Pediatric Vasoactive Intestinal Peptide Secreting Tumor With Literature Review: A Challenging Etiology of Chronic Diarrhea.

Front Pediatr 2020 5;8:430. Epub 2020 Aug 5.

Division of Pediatric Gastroenterology, Department of Pediatrics, Chang Gung Memorial Hospital, Linkou Branch and Chang Gung University College of Medicine, Taoyuan City, Taiwan.

Vasoactive intestinal peptide (VIP) secreting tumor (VIPoma) is a rare disease, presenting with profuse diarrhea, electrolyte imbalance, and possibly fatal outcome. The diagnosis and treatment are challenging, and no consensus guideline of management is available. The pediatric incidence remains unclear. Read More

View Article and Full-Text PDF

Incidental 68Ga-DOTATATE uptake in the pancreatic head: A case report and a unique opportunity to improve clinical care.

Medicine (Baltimore) 2020 May;99(22):e20197

Radiology and Imaging Sciences, Clinical Center.

Rationale: Neuroendocrine tumors (NETs) are neoplasms that can arise from the neuroendocrine cells distributed widely throughout the body. Majority of NETs overexpress somatostatin receptors (SSTR) on their cell surface. This biologic characteristic is exploited by SSTR-based imaging such as In octreotide scintigraphy and Ga DOTATATE positron emission tomography (PET)/computed tomography (CT), which are considered standard for initial evaluation of NETs. Read More

View Article and Full-Text PDF

A Rare Cause of Refractory Chronic Diarrhea and Cachexia: A Case Report.

Iran J Public Health 2020 Feb;49(2):386-388

Department of Endocrinology, Hedi Chaker Hospital, Sfax, Tunisia.

VIPoma is an unusual neuroendocrine neoplasm that autonomously secretes VIP. It is associated with secretory diarrhea and electrolyte disturbances. Herein we report a case of a male patient, who was hospitalized in the Department of Endocrinology in Hedi Chaker Hospital, Sfax, Tunisia. Read More

View Article and Full-Text PDF
February 2020

Neuroendocrine pancreatic tumor causing chronic diarrhea in young adult, a case report.

AME Case Rep 2020 30;4:13. Epub 2020 Apr 30.

Digestive System Surgery Service at Getúlio Vargas Teaching Hospital (HUGV), Manaus, Amazonas, Brazil.

Secretory tumors of vasoactive intestinal polypeptides (VIPomas) are rare neuroendocrine pancreatic neoplasms usually associated with secretory diarrhea. Most cases present themselves with diarrhea, weight loss, and hypokalemia. Although VIPoma patients share easily distinguishable symptoms, early diagnosis remains a challenge. Read More

View Article and Full-Text PDF

Hypercalcemia in a Patient Diagnosed with a Vasoactive Intestinal Peptide Tumor.

Cureus 2020 Feb 4;12(2):e6882. Epub 2020 Feb 4.

Medicine, Renaissance School of Medicine, Stony Brook University, Stony Brook, USA.

Hypercalcemia is a clinical problem that is commonly seen in both the inpatient and outpatient settings. Overall, most common causes of hypercalcemia include hyperparathyroidism and malignancy. Our case report is the presentation of hypercalcemia in a patient eventually diagnosed with a vasoactive intestinal peptide tumor, a type of neuroendocrine tumor, without associated hyperparathyroidism. Read More

View Article and Full-Text PDF
February 2020